In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d

Charlotte Fuller; Zain Chagla

doi:10.7326/J23-0020

In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d

Ann Intern Med. 2023 Apr;176(4):JC41. doi: 10.7326/J23-0020. Epub 2023 Apr 4.

Authors

Charlotte Fuller¹, Zain Chagla¹

Affiliation

¹ McMaster University, Hamilton, Ontario, Canada (C.F., Z.C.).

PMID: 37011390
DOI: 10.7326/J23-0020

Abstract

Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.

Publication types

Randomized Controlled Trial
Comment

MeSH terms

COVID-19*
Critical Illness
Humans
Receptors, Interleukin-6

Substances

Receptors, Interleukin-6